VAPING168 reports,British American Tobacco has conducted the first study of its e-cigarette brand, Vuse, to assess and provide insights into the actual health effects of e-cigarettes.
The study compared biomarker measurements in Vuse consumers who had used the product for more than six months with results from smokers, former smokers and never smokers. Details of the protocol explaining the innovative design of the latest study are published in the Journal of Health and Environmental Research.
The cross-sectional study design used a set of data readouts to measure indicators of exposure to certain toxicants and potential harm associated with several smoking-related diseases in people using Vuse alone.
British American Tobacco hopes that the results, currently being analysed and to be released later this year, will provide further supportive evidence that the use of Vuse reduces the relative risk of certain diseases in adult consumers compared with smoking.
The company expects that, once available, the results will add to the growing body of evidence of Vuse’s potential as a risk-reducing product.
“This innovative study demonstrates our commitment to investigating the risk reduction potential of a new class of products,” said Sharon Goodall, head of regulatory science at British American Tobacco, in a statement.
“What makes it particularly relevant and exciting is that the results generated will be from people who have been using Vuse for more than six months prior to testing. The results will provide important new insights and show us how Vuse users, smokers and Differences in ex-smokers across a range of important biomarkers thought to predict disease progression. We look forward to sharing data as they become available.”